CSPG4 and melanoma: highlighted that chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR NKT cells, designed for melanoma, maintained the ability to eliminate target cells through their endogenous TCRs, a mechanism independent from CAR-induced activity.